Natural Killer T Cells in Advanced Melanoma Patients Treated with Tremelimumab

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Ibarrondo, F Javier ^a   Yang, Otto O ^a   Chodon, Thinle ^a   Avramis, Earl ^a   Lee, Yohan ^b   Sazegar, Hooman ^a   Jalil, Jason ^a   Chmielowski, Bartosz ^a   Koya, Richard C ^a   Schmid, Ingrid ^a   Gomez Navarro, Jesus ^c,e   Jamieson, Beth D ^a   Ribas, Antoni ^a,d   Comin Anduix, Begoña ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MILLENNIUM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; TICILIMUMAB; ANTINEOPLASTIC AGENT; MELAN A; MONOCLONAL ANTIBODY;

ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MELANOMA; MONOTHERAPY; NATURAL KILLER T CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHENOTYPE; TH1 CELL; TH2 CELL; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; IMMUNOLOGY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNITY, CELLULAR; MALE; MART-1 ANTIGEN; MELANOMA; NATURAL KILLER T-CELLS; TH1 CELLS; TH2 CELLS;

EID: 84885962689     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076829     Document Type: Article

References (61)

1. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG, (2000) NKT cells: facts, functions and fallacies. Immunol Today 21: 573-583.
2. Brigl M, Brenner MB, (2004) CD1: Antigen Presentation and T Cell Function. Annu Rev Immunol 22: 817-890.
3. Godfrey DI, Rossjohn J, (2011) New ways to turn on NKT cells. J Exp Med 208: 1121-1125 jem.20110983 [pii];10.1084/jem.20110983 [doi].
4. Joyce S, Girardi E, Zajonc DM, (2011) NKT cell ligand recognition logic: molecular basis for a synaptic duet and transmission of inflammatory effectors. J Immunol 187: 1081-1089 187/3/1081 [pii];10.4049/jimmunol.1001910 [doi].
5. Yang OO, Racke FK, Nguyen PT, Gausling R, Severino ME, et al. (2000) CD1d on myeloid dendritic cells stimulates cytokine secretion from and cytolytic activity of V alpha 24J alpha Q T cells: a feedback mechanism for immune regulation. J Immunol 165: 3756-3762.
6. Brigl M, Tatituri RV, Watts GF, Bhowruth V, Leadbetter EA, et al. (2011) Innate and cytokine-driven signals, rather than microbial antigens, dominate in natural killer T cell activation during microbial infection. J Exp Med 208: 1163-1177 jem.20102555 [pii];10.1084/jem.20102555 [doi].
7. Berzins SP, Smyth MJ, Baxter AG, (2011) Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 11: 131-142 nri2904 [pii];10.1038/nri2904 [doi].
8. Gansert JL, Kiessler V, Engele M, Wittke F, Rollinghoff M, et al. (2003) Human NKT cells express granulysin and exhibit antimycobacterial activity. Journal of Immunology 170: 3154-3161.
9. Chan WL, Pejnovic N, Liew TV, Lee CA, Groves R, et al. (2003) NKT cell subsets in infection and inflammation. Immunol Lett 85: 159-163.
10. Milpied P, Massot B, Renand A, Diem S, Herbelin A, et al. (2011) IL-17-producing invariant NKT cells in lymphoid organs are recent thymic emigrants identified by neuropilin-1 expression. Blood 118: 2993-3002 blood-2011-01-329268 [pii];10.1182/blood-2011-01-329268 [doi].
11. Ibarrondo FJ, Wilson SB, Hultin LE, Shih R, Hausner MA, et al. (2012) Preferential depletion of gut CD4-expressing iNKT cells contributes to systemic immune activation in HIV-1 infection. Mucosal Immunol. mi2012101 [pii];10.1038/mi.2012.101 [doi].
12. Kronenberg M, (2005) Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 23: 877-900.
13. Kawano T, Nakayama T, Kamada N, Kaneko Y, Harada M, et al. (1999) Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells. Cancer Res 59: 5102-5105.
14. Crough T, Purdie DM, Okai M, Maksoud A, Nieda M, et al. (2004) Modulation of human Valpha24(+)Vbeta11(+) NKT cells by age, malignancy and conventional anticancer therapies. Br J Cancer 91: 1880-1886 6602218 [pii];10.1038/sj.bjc.6602218 [doi].
15. Tahir SM, Cheng O, Shaulov A, Koezuka Y, Bubley GJ, et al. (2001) Loss of IFN-gamma production by invariant NK T cells in advanced cancer. J Immunol 167: 4046-4050.
16. van der Vliet HJ, Molling JW, Nishi N, Masterson AJ, Kolgen W, et al. (2003) Polarization of Valpha24+ Vbeta11+ natural killer T cells of healthy volunteers and cancer patients using alpha-galactosylceramide-loaded and environmentally instructed dendritic cells. Cancer Res 63: 4101-4106.
17. Molling JW, Kolgen W, Boomsma MF, Kruizenga H, et al. (2005) Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer 116: 87-93.
18. Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, et al. (2005) A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 11: 1910-1917 11/5/1910 [pii];10.1158/1078-0432.CCR-04-1453 [doi].
19. Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, et al. (2006) A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 12: 6079-6086.
20. Motohashi S, Okamoto Y, Yoshino I, Nakayama T, (2011) Anti-tumor immune responses induced by iNKT cell-based immunotherapy for lung cancer and head and neck cancer. Clin Immunol 140: 167-176 S1521-6616(11)00028-3 [pii];10.1016/j.clim.2011.01.009 [doi].
21. Molling JW, Moreno M, van der Vliet HJ, van den Eertwegh AJ, Scheper RJ, et al. (2008) Invariant natural killer T cells and immunotherapy of cancer. Clin Immunol 129: 182-194 S1521-6616(08)00759-6 [pii];10.1016/j.clim.2008.07.025 [doi].
22. Terabe M, Berzofsky JA, (2008) The role of NKT cells in tumor immunity. Adv Cancer Res 101: 277-348 S0065-230X(08)00408-9 [pii];10.1016/S0065-230X(08)00408-9 [doi].
23. Exley MA, Lynch L, Varghese B, Nowak M, Alatrakchi N, et al. (2011) Developing understanding of the roles of CD1d-restricted T cell subsets in cancer: reversing tumor-induced defects. Clin Immunol 140: 184-195 S1521-6616(11)00157-4 [pii];10.1016/j.clim.2011.04.017 [doi].
24. Gilboa E, (2007) DC-based cancer vaccines. J Clin Invest 117: 1195-1203 10.1172/JCI31205 [doi].
25. Nakai N, Hartmann G, Kishimoto S, Katoh N, (2010) Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters. Pigment Cell Melanoma Res 23: 607-619 PCR736 [pii];10.1111/j.1755-148X.2010.00736.x [doi].
26. Peggs KS, Quezada SA, Korman AJ, Allison JP, (2006) Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18: 206-213.
27. Agarwala SS, Ribas A, (2010) Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors. J Immunother 33: 557-569 10.1097/CJI.0b013e3181dcd260 [doi].
28. Ribas A, Hanson DC, Noe DA, Millham R, Guyot DJ, et al. (2007) Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12: 873-883 12/7/873 [pii];10.1634/theoncologist.12-7-873 [doi].
29. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, et al. (2009) Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol 27: 1075-1081 JCO.2008.19.2435 [pii];10.1200/JCO.2008.19.2435 [doi].
30. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, et al. (2005) Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol 23: 8968-8977 JCO.2005.01.109 [pii];10.1200/JCO.2005.01.109 [doi].
31. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, et al. (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723 NEJMoa1003466 [pii];10.1056/NEJMoa1003466 [doi].
32. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, et al. (2008) Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med 6: 22 1479-5876-6-22 [pii];10.1186/1479-5876-6-22 [doi].
33. Comin-Anduix B, Sazegar H, Chodon T, Matsunaga D, Jalil J, et al. (2010) Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma. PLoS One 5: e12711 10.1371/journal.pone.0012711 [doi].
34. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, et al. (2009) Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 15: 6267-6276 1078-0432.CCR-09-1254 [pii];10.1158/1078-0432.CCR-09-1254 [doi].
35. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2 92(3): 205-16.
36. Tumeh PC, Koya RC, Chodon T, Graham NA, Graeber TG, et al. (2010) The impact of ex vivo clinical grade activation protocols on human T-cell phenotype and function for the generation of genetically modified cells for adoptive cell transfer therapy. J Immunother. 2010 Oct 33(8): 759-68 doi: 10.1097/CJI.0b013e3181f1d644.
37. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A, (1999) Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401: 708-712 10.1038/44385 [doi].
38. Sallusto F, Geginat J, Lanzavecchia A, (2004) Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 22: 745-763 10.1146/annurev.immunol.22.012703.104702 [doi].
39. Wolfl M, Kuball J, Ho WY, Nguyen H, Manley TJ, et al. (2007) Activation-induced expression of CD137 permits detection, isolation, and expansion of the full repertoire of CD8+ T cells responding to antigen without requiring knowledge of epitope specificities. Blood 110: 201-210 blood-2006-11-056168 [pii];10.1182/blood-2006-11-056168 [doi].
40. Vinay DS, Kwon BS, (1998) Role of 4-1BB in immune responses. Semin Immunol 10: 481-489 S1044-5323(98)90157-9 [pii];10.1006/smim.1998.0157 [doi].
41. Kelly-Rogers J, Madrigal-Estebas L, O'Connor T, Doherty DG, (2006) Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Hum Immunol 67: 863-873 S0198-8859(06)00484-8 [pii];10.1016/j.humimm.2006.08.292 [doi].
42. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, et al. (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854 10.1126/science.1076514 [doi];1076514 [pii].
43. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA, (2003) Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 26: 332-342.
44. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, et al. (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26: 5233-5239 JCO.2008.16.5449 [pii];10.1200/JCO.2008.16.5449 [doi].
45. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, et al. (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9: 998-1008.
46. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, et al. (2004) Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother 27: 354-367. 00002371-200409000-00004 [pii].
47. Emoto M, Zerrahn J, Miyamoto M, Perarnau B, Kaufmann SH, (2000) Phenotypic characterization of CD8(+)NKT cells. Eur J Immunol 30: 2300-2311 10.1002/1521-4141(2000)30:8<2300::AID-IMMU2300>3.0.CO;2-2 [pii];10.1002/1521-4141(2000)30:8-2300::AID-IMMU2300-3.0.CO;2-2 [doi].
48. Godfrey DI, Stankovic S, Baxter AG, (2010) Raising the NKT cell family. Nat Immunol 11: 197-206 ni.1841 [pii];10.1038/ni.1841 [doi].
49. Assenmacher M, Schmitz J, Radbruch A. (1994) Flow cytometry determination if cytokines in activated murine T helper lymphocytes: Expresson of interleukin-10 in interferon-g and in interleukin-4-expressing cells. Eur. J. of Immuno. Vol 24 Issue5, pag 1097-1101. DOI: 10.1002/eji.1830240513.
50. Wilson SB, Delovitch TL, (2003) Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 3: 211-222.
51. Wilson SB, Delovitch TL, (2003) Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat Rev Immunol 3: 211-222 10.1038/nri1028 [doi];nri1028 [pii].
52. Watarai H, Rybouchkin A, Hongo N, Nagata Y, Sakata S, et al. (2010) Generation of functional NKT cells in vitro from embryonic stem cells bearing rearranged invariant Valpha14-Jalpha18 TCRalpha gene. Blood 115: 230-237 blood-2009-04-217729 [pii];10.1182/blood-2009-04-217729 [doi].
53. Yang OO, Wilson SB, Hultin LE, Detels R, Hultin PM, et al. (2007) Delayed reconstitution of CD4+ iNKT cells after effective HIV type 1 therapy. AIDS Res Hum Retroviruses 23: 913-922.
54. Kim CH, Johnston B, Butcher EC, (2002) Trafficking machinery of NKT cells: shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity. Blood 100: 11-16 10.1182/blood-2001-12-0196 [doi].
55. Montoya CJ, Catano JC, Ramirez Z, Rugeles MT, Wilson SB, et al. (2008) Invariant NKT cells from HIV-1 or Mycobacterium tuberculosis-infected patients express an activated phenotype. Clin Immunol 127: 1-6 S1521-6616(07)01442-8 [pii];10.1016/j.clim.2007.12.006 [doi].
56. Mellman I, Coukos G, Dranoff G, (2011) Cancer immunotherapy comes of age. Nature 480: 480-489 nature10673 [pii];10.1038/nature10673 [doi].
57. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, et al. (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366: 2455-2465 10.1056/NEJMoa1200694 [doi].
58. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, et al. (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366: 2443-2454 10.1056/NEJMoa1200690 [doi].
59. Li X, Fujio M, Imamura M, Wu D, Vasan S, et al. (2010) Design of a potent CD1d-binding NKT cell ligand as a vaccine adjuvant. Proc Natl Acad Sci U S A 107: 13010-13015 1006662107 [pii];10.1073/pnas.1006662107 [doi].
60. Watarai H, Yamada D, Fujii S, Taniguchi M, Koseki H, (2012) Induced pluripotency as a potential path towards iNKT cell-mediated cancer immunotherapy. Int J Hematol 95: 624-631 10.1007/s12185-012-1091-0 [doi].
61. Perfetto SP, Chattopadhyay PK, Roederer M, (2004) Seventeen-colour flow cytometry: unravelling the immune system. Nat Rev Immunol 4: 648-655.